CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics
Summary
The companys strong growth has been fueled by its innovative Syn-One Test\xae that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinsons disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders. Additionally, Syn-One Biomarker Technology, which leverages CNDs AI-assisted platform NerValence to quantify the amount of synuclein detected in cutaneous nerves, is being applied in multiple pharmaceutical clinical trials with the hope of measuring an investigational drugs effect on the pathological protein. "Without accurate diagnosis and objective measures of disease progression and therapy response, treatment of the synuclein-related disorders will be hampered," said Christopher Gibbons, MD, chief scientific officer of CND. "We are encouraged by the strong adoption of CNDs innovative testing that is providing actionable information to ordering clinicians and closing gaps in care for patients facing neurodegenerative diseases. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinsons disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder.